Piperlonguminine is neuroprotective in experimental rat stroke

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Inflammatory damage is a key factor in the pathogenesis of cerebral ischemia.
• Piperlonguminine (PE) exhibits known anti-inflammatory properties.
• Targeting inflammatory pathways presents a potential therapeutic approach for ischemic stroke.

Purpose of the Study:

• To investigate the neuroprotective effects of Piperlonguminine (PE) in vitro and in vivo.
• To determine the impact of PE on neuronal cell damage and inflammatory signaling in cerebral ischemia models.

Main Methods:

• In vitro: SH-SY5Y neuronal cells were subjected to oxygen-glucose deprivation (OGD) or tumor necrosis factor-α (TNF-α) stimulation, with or without PE treatment.
• In vivo: Rats underwent middle cerebral artery occlusion (MCAO) followed by reperfusion, with PE administered intraperitoneally.
• Assessed cytotoxicity, apoptosis, NF-κB and MAPK activation, neurological deficit scores, infarct volume, brain water content, and blood-brain barrier (BBB) integrity.

Main Results:

• PE treatment reduced OGD-induced cytotoxicity and apoptosis in SH-SY5Y cells.
• PE inhibited TNF-α-induced activation of NF-κB and MAPK signaling pathways.
• In vivo, PE significantly attenuated neurological deficits, reduced infarct volume and brain water content, and inhibited NF-κB and MAPK activation in MCAO rats.

Conclusions:

• Piperlonguminine (PE) demonstrates significant neuroprotective potential against cerebral ischemic injury.
• PE alleviates brain damage by inhibiting inflammatory signaling pathways, including NF-κB and MAPK.
• PE's mechanism involves mitigating blood-brain barrier (BBB) breakdown, suggesting its therapeutic promise for stroke.